BioCryst Pharmaceuticals | BCRX - Current Liabilities


BioCryst Pharmaceuticals reported $195.83M in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
Alnylam Pharmaceuticals USD 2.06B 550.49M Sep/2026
BioCryst Pharmaceuticals USD 195.83M 13.02M Sep/2026
Chugai Pharma JPY 256.57B 135.62B Sep/2026
Daiichi Sankyo JPY 882.78B 117.08B Sep/2026
DBV Technologies USD 58.5M 4.2M Sep/2026
Enanta Pharmaceuticals USD 44.73M 3.83M Dec/2025
Gilead Sciences USD 12B 982M Sep/2026
GlaxoSmithKline GBP 20.72B 814M Sep/2026
Glaxosmithkline GBP 20.72B 1.71B Sep/2026
Incyte USD 1.44B 125.72M Sep/2026
Ionis Pharmaceuticals USD 315.64M 401.36M Jun/2026
Karyopharm Therapeutics USD 117.3M 25.24M Mar/2026
Neurocrine Biosciences USD 984.6M 110.1M Sep/2026
Novavax USD 329.84M 729K Sep/2026
PTC Therapeutics USD 776.08M 5.01M Sep/2026
Regeneron Pharmaceuticals USD 6.2B 671.5M Sep/2026
Roche Holding CHF 28.85B 846M Jun/2026
Sarepta Therapeutics USD 656.35M 153.44M Sep/2026
Ultragenyx Pharmaceutical USD 389M 38M Sep/2026
Vertex Pharmaceuticals USD 5B 1.06B Sep/2026